Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study
OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven...
Gespeichert in:
| Veröffentlicht in: | EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY 2023-05, Vol.63 (5) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | |
| container_title | EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY |
| container_volume | 63 |
| creator | Abdelshafy, Mahmoud Caliskan, Kadir Simpkin, Andrew J Elkoumy, Ahmed Kimman, Jesse R Elsherbini, Hagar Elzomor, Hesham de By, Theo M.M.H Gollmann-Tepekoylu, Can Berchtold-Herz, Michael Loforte, Antonio Reineke, David Schoenrath, Felix Paluszkiewicz, Lech Gummert, Jan Mohacsi, Paul Meyns, Bart Soliman, Osama |
| description | OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS: The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS: In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P |
| format | Article |
| fullrecord | <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_719650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_719650</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7196503</originalsourceid><addsrcrecordid>eNqVTstKw0AUzULBWv2HuxYik6RtyLLUiItKoWq3w2Vyk44mM2HuTDC_5teZiB-gq3M4nNdFtEhEIuK8WImr6Jr5XQixydJ8EX2Vda0VqhFsDS0NlnVHpkID2tSBtZ0J9Og1Gc8QTEWusdo0gJO99jBMutMqtOgAmTV7qGjQikB3fYvGz3mE3tmeDGs_AivrCDr06kwVoMF2nGLzvj8TlG_Hw_N29wKOmqnMjfGPGpyFfXk6xPvT9gHYh2q8iS5rbJluf3EZ3T2Wr7un-CO0FKZfsuIeFclUyLUQMkmLVSrzpNisRbaM7v9slv7TZ_9q_wba1nZq</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study</title><source>Lirias (KU Leuven Association)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Abdelshafy, Mahmoud ; Caliskan, Kadir ; Simpkin, Andrew J ; Elkoumy, Ahmed ; Kimman, Jesse R ; Elsherbini, Hagar ; Elzomor, Hesham ; de By, Theo M.M.H ; Gollmann-Tepekoylu, Can ; Berchtold-Herz, Michael ; Loforte, Antonio ; Reineke, David ; Schoenrath, Felix ; Paluszkiewicz, Lech ; Gummert, Jan ; Mohacsi, Paul ; Meyns, Bart ; Soliman, Osama</creator><creatorcontrib>Abdelshafy, Mahmoud ; Caliskan, Kadir ; Simpkin, Andrew J ; Elkoumy, Ahmed ; Kimman, Jesse R ; Elsherbini, Hagar ; Elzomor, Hesham ; de By, Theo M.M.H ; Gollmann-Tepekoylu, Can ; Berchtold-Herz, Michael ; Loforte, Antonio ; Reineke, David ; Schoenrath, Felix ; Paluszkiewicz, Lech ; Gummert, Jan ; Mohacsi, Paul ; Meyns, Bart ; Soliman, Osama</creatorcontrib><description>OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS: The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS: In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality. CONCLUSIONS: In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.</description><identifier>ISSN: 1010-7940</identifier><language>eng</language><publisher>OXFORD UNIV PRESS INC</publisher><ispartof>EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023-05, Vol.63 (5)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,316,781,785,27864</link.rule.ids></links><search><creatorcontrib>Abdelshafy, Mahmoud</creatorcontrib><creatorcontrib>Caliskan, Kadir</creatorcontrib><creatorcontrib>Simpkin, Andrew J</creatorcontrib><creatorcontrib>Elkoumy, Ahmed</creatorcontrib><creatorcontrib>Kimman, Jesse R</creatorcontrib><creatorcontrib>Elsherbini, Hagar</creatorcontrib><creatorcontrib>Elzomor, Hesham</creatorcontrib><creatorcontrib>de By, Theo M.M.H</creatorcontrib><creatorcontrib>Gollmann-Tepekoylu, Can</creatorcontrib><creatorcontrib>Berchtold-Herz, Michael</creatorcontrib><creatorcontrib>Loforte, Antonio</creatorcontrib><creatorcontrib>Reineke, David</creatorcontrib><creatorcontrib>Schoenrath, Felix</creatorcontrib><creatorcontrib>Paluszkiewicz, Lech</creatorcontrib><creatorcontrib>Gummert, Jan</creatorcontrib><creatorcontrib>Mohacsi, Paul</creatorcontrib><creatorcontrib>Meyns, Bart</creatorcontrib><creatorcontrib>Soliman, Osama</creatorcontrib><title>Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study</title><title>EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY</title><description>OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS: The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS: In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality. CONCLUSIONS: In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.</description><issn>1010-7940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVTstKw0AUzULBWv2HuxYik6RtyLLUiItKoWq3w2Vyk44mM2HuTDC_5teZiB-gq3M4nNdFtEhEIuK8WImr6Jr5XQixydJ8EX2Vda0VqhFsDS0NlnVHpkID2tSBtZ0J9Og1Gc8QTEWusdo0gJO99jBMutMqtOgAmTV7qGjQikB3fYvGz3mE3tmeDGs_AivrCDr06kwVoMF2nGLzvj8TlG_Hw_N29wKOmqnMjfGPGpyFfXk6xPvT9gHYh2q8iS5rbJluf3EZ3T2Wr7un-CO0FKZfsuIeFclUyLUQMkmLVSrzpNisRbaM7v9slv7TZ_9q_wba1nZq</recordid><startdate>20230502</startdate><enddate>20230502</enddate><creator>Abdelshafy, Mahmoud</creator><creator>Caliskan, Kadir</creator><creator>Simpkin, Andrew J</creator><creator>Elkoumy, Ahmed</creator><creator>Kimman, Jesse R</creator><creator>Elsherbini, Hagar</creator><creator>Elzomor, Hesham</creator><creator>de By, Theo M.M.H</creator><creator>Gollmann-Tepekoylu, Can</creator><creator>Berchtold-Herz, Michael</creator><creator>Loforte, Antonio</creator><creator>Reineke, David</creator><creator>Schoenrath, Felix</creator><creator>Paluszkiewicz, Lech</creator><creator>Gummert, Jan</creator><creator>Mohacsi, Paul</creator><creator>Meyns, Bart</creator><creator>Soliman, Osama</creator><general>OXFORD UNIV PRESS INC</general><scope>FZOIL</scope></search><sort><creationdate>20230502</creationdate><title>Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study</title><author>Abdelshafy, Mahmoud ; Caliskan, Kadir ; Simpkin, Andrew J ; Elkoumy, Ahmed ; Kimman, Jesse R ; Elsherbini, Hagar ; Elzomor, Hesham ; de By, Theo M.M.H ; Gollmann-Tepekoylu, Can ; Berchtold-Herz, Michael ; Loforte, Antonio ; Reineke, David ; Schoenrath, Felix ; Paluszkiewicz, Lech ; Gummert, Jan ; Mohacsi, Paul ; Meyns, Bart ; Soliman, Osama</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7196503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdelshafy, Mahmoud</creatorcontrib><creatorcontrib>Caliskan, Kadir</creatorcontrib><creatorcontrib>Simpkin, Andrew J</creatorcontrib><creatorcontrib>Elkoumy, Ahmed</creatorcontrib><creatorcontrib>Kimman, Jesse R</creatorcontrib><creatorcontrib>Elsherbini, Hagar</creatorcontrib><creatorcontrib>Elzomor, Hesham</creatorcontrib><creatorcontrib>de By, Theo M.M.H</creatorcontrib><creatorcontrib>Gollmann-Tepekoylu, Can</creatorcontrib><creatorcontrib>Berchtold-Herz, Michael</creatorcontrib><creatorcontrib>Loforte, Antonio</creatorcontrib><creatorcontrib>Reineke, David</creatorcontrib><creatorcontrib>Schoenrath, Felix</creatorcontrib><creatorcontrib>Paluszkiewicz, Lech</creatorcontrib><creatorcontrib>Gummert, Jan</creatorcontrib><creatorcontrib>Mohacsi, Paul</creatorcontrib><creatorcontrib>Meyns, Bart</creatorcontrib><creatorcontrib>Soliman, Osama</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdelshafy, Mahmoud</au><au>Caliskan, Kadir</au><au>Simpkin, Andrew J</au><au>Elkoumy, Ahmed</au><au>Kimman, Jesse R</au><au>Elsherbini, Hagar</au><au>Elzomor, Hesham</au><au>de By, Theo M.M.H</au><au>Gollmann-Tepekoylu, Can</au><au>Berchtold-Herz, Michael</au><au>Loforte, Antonio</au><au>Reineke, David</au><au>Schoenrath, Felix</au><au>Paluszkiewicz, Lech</au><au>Gummert, Jan</au><au>Mohacsi, Paul</au><au>Meyns, Bart</au><au>Soliman, Osama</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study</atitle><jtitle>EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY</jtitle><date>2023-05-02</date><risdate>2023</risdate><volume>63</volume><issue>5</issue><issn>1010-7940</issn><abstract>OBJECTIVES: Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS: The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS: In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2- 5.5) vs 2 (2- 4); P < 0.001], received more right ventricular assist devices (RVAD) [32 (8%) vs 178 (5.5%); P = 0.038] and stayed longer in the intensive care unit post-LVAD implant [19 (8-35) vs 11(5-25); P < 0.001]. Yet, there was no significant difference in the rate of RHF, 30-day, or 1-year mortality. Also, in the matched cohort (357 patients taking levosimendan compared to an average of 622 controls across 20 imputations), we found no evidence for a difference in postoperative severe RHF, RVAD implant rate, length of stay in the intensive care unit or 30-day and 1-year mortality. CONCLUSIONS: In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.</abstract><pub>OXFORD UNIV PRESS INC</pub><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-7940 |
| ispartof | EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2023-05, Vol.63 (5) |
| issn | 1010-7940 |
| language | eng |
| recordid | cdi_kuleuven_dspace_20_500_12942_719650 |
| source | Lirias (KU Leuven Association); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| title | Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry-the Euro LEVO-LVAD study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T01%3A28%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20levosimendan%20infusion%20in%20patients%20undergoing%20a%20left%20ventricular%20assist%20device%20implant%20in%20a%20propensity%20score%20matched%20analysis%20of%20the%20EUROMACS%20registry-the%20Euro%20LEVO-LVAD%20study&rft.jtitle=EUROPEAN%20JOURNAL%20OF%20CARDIO-THORACIC%20SURGERY&rft.au=Abdelshafy,%20Mahmoud&rft.date=2023-05-02&rft.volume=63&rft.issue=5&rft.issn=1010-7940&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_719650%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |